Results 51 to 60 of about 89 (70)

Development of HPLC and LC–MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016
Felisa Reyes-Ortega, Dominic Keating, Jian Li   +2 more
exaly  

Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1

Journal of Cystic Fibrosis, 2019
Susanna A Mccolley, Michael W Konstan, Claire E Wainwright   +2 more
exaly  

Ivacaftor/lumacaftor

Reactions Weekly
openaire   +1 more source

Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation

Value in Health, 2017
Piyameth Dilokthornsakul, Jonathan D Campbell   +1 more
exaly  

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor

Therapeutic Advances in Respiratory Disease, 2019
Jaime L Rubin, Michael W Konstan, Conor Chandler   +2 more
exaly  

Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding

Journal of Cystic Fibrosis, 2018
Aaron Trimble, Cameron J Mckinzie, Elizabeth Stringer   +2 more
exaly  

Lumacaftor/ivacaftor initiation in two liver transplantation patients under tacrolimus and antifungal azoles

Clinical Case Reports (discontinued), 2019
Philippe Reix
exaly  

Isavuconazole/ivacaftor/lumacaftor

Reactions Weekly, 2019
openaire   +1 more source

Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor

Pediatric Pulmonology, 2019
Sachinkumar B Singh, Logan T Murry, Ashley Sabus   +2 more
exaly  

Fluoxetine/ivacaftor/lumacaftor

Reactions Weekly, 2017
openaire   +1 more source